You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Gene Therapy: New Hope for Patients With CHM and XLRP

  • Authors: Mark Pennesi, MD, PhD; Byron L. Lam, MD; Dominik Fischer, MD, PhD
  • CME Released: 5/14/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 5/14/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for ophthalmologists, pediatricians, and primary care physicians.
 

The goal of this activity is to increase the detection and diagnosis rates of patients with inherited retinal degenerations (IRDs) and keep clinicians abreast of the latest data of evolving gene therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Signs and symptoms of IRDs on first presentation
    • Diagnostic modalities for IRDs
    • Clinical trial data for emerging treatment options for IRDs


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Mark Pennesi, MD, PhD

    Associate Professor of Ophthalmology
    Kenneth C. Swan Endowed Professor
    Division Chief, Ophthalmic Genetics
    Casey Eye Institute
    Oregon Health & Science University
    Portland, Oregon, United States

    Disclosures

    Disclosure: Mark Pennesi, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allegran/Editas; Astellas Pharmaceuticals; Biogen Horama; Eyevensys; IVERIC; Nacuity Pharmaceuticals; Nayan; Ocugen; Sparks Therapeutics
    Received grants for clinical research from: Nacuity Pharmaceuticals; Ocugen 

  • Byron L. Lam, MD

    Robert Z. and Nancy J. Greene Chair in Ophthalmology
    Professor of Ophthalmology
    University of Miami Miller School of Medicine
    Miami, Florida, United States

    Disclosures

    Disclosure: Byron L. Lam, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan; Nightstar; ProQR
    Received grants for clinical research from: AGTC; Allergan; Biogen; Editas; Evision; FFB; Pixium; ProQR; Regenera

  • Dominik Fischer, MD, PhD

    Professor of Ophthalmology
    Institute for Ophthalmic Research
    University of Tübingen
    Tübingen, Germany

    Disclosures

    Disclosure: Dominik Fischer, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adelphi Values; Casebia; Covance; EyeServ; Hoffman Eitle; Horoma; Nightstar; Janssen; Roche; Sanofi; STZeyetrial; Topivert
    Received grants for clinical research from: Bayer; Biogen; Casebia; Nightstar; Novartis

Editors

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

  • Anita A. Galdieri, PharmD, RPh

    Senior Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Anita A. Galdieri, PharmD, RPh, has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director
    Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Apellis; DeepMind Technologies Inc; Roche; Novartis Owns stock, stock options, or bonds from: Big Picture Medical Other: Speaker fees: Allergan; Bayer; Heidelberg Engineering; Topcon


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Gene Therapy: New Hope for Patients With CHM and XLRP

Authors: Mark Pennesi, MD, PhD; Byron L. Lam, MD; Dominik Fischer, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 5/14/2020

Valid for credit through: 5/14/2021, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Challenges in Detection and Diagnosis of Inherited Retinal Degenerations

Dr Mark Pennesi reviews diagnosis of IRDs, including differentiation of retinitis pigmentosa (RP).
Mark Pennesi, MD, PhD

Choroideremia

Dr Byron Lam discusses the clinical findings and treatment of choroideremia.
Byron L. Lam, MD

X-Linked Retinitis Pigmentosa (XLRP)

Dr Dominik Fischer discusses emerging therapy for X-linked retinitis pigmentosa (XLRP).
Dominik Fischer, MD, PhD
 

Pre-assessment question

The goal of this activity is to increase the detection and diagnosis rates of patients with inherited retinal degenerations (IRDs) and keep clinicians abreast of the latest data of evolving gene therapies.

Before you begin this activity, please complete this brief survey. 
 

  • Print